Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1067 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 44, which is 18 points higher than the healthcare sector average of 26. It passed 14 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 77.24% over the past year, overperforming other healthcare stocks by 173 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 24.28% from Bioventus's current stock price of $12.07.

Bioventus stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Bioventus, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Immucell (NASDAQ:ICCC) is the #2 top healthcare stock out of 1067 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Immucell (NASDAQ:ICCC) is: Value: C, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Immucell (NASDAQ:ICCC) has a Due Diligence Score of 19, which is -7 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates ICCC as a "A".It passed 6 out of 33 due diligence checks and has weak fundamentals. Immucell has seen its stock return 70.46% over the past year, overperforming other healthcare stocks by 166 percentage points.

Neurocrine Biosciences (NASDAQ:NBIX) is the #3 top healthcare stock out of 1067 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Neurocrine Biosciences (NASDAQ:NBIX) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: B.

Neurocrine Biosciences (NASDAQ:NBIX) has a Due Diligence Score of 72, which is 46 points higher than the healthcare sector average of 26. It passed 24 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 28.84% over the past year, overperforming other healthcare stocks by 124 percentage points.

Neurocrine Biosciences has an average 1 year price target of $192.33, an upside of 10.47% from Neurocrine Biosciences's current stock price of $174.10.

Neurocrine Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 18 analysts covering Neurocrine Biosciences, 50% have issued a Strong Buy rating, 38.89% have issued a Buy, 11.11% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 77 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Esperion Therapeutics (NASDAQ:ESPR) has an annual dividend yield of 99.37%, which is 95 percentage points higher than the healthcare sector average of 3.93%.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 34.95%, which is 31 percentage points higher than the healthcare sector average of 3.93%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 16.62%, which is 13 percentage points higher than the healthcare sector average of 3.93%.

Siga Technologies's dividend payout ratio of 206.9% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.7% in the last day, and down -1.36% over the last week. Bnb Plus was the among the top losers in the healthcare sector, dropping -57.11% yesterday.

BNB Plus shares are trading lower after the company announced it received a Nasdaq delisitng notification.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 43, which is 29 points higher than the healthcare sector average of 14. It passed 3 out of 7 valuation due diligence checks.

Embecta's stock has dropped -69.05% in the past year. It has overperformed other stocks in the healthcare sector by 26 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 72 points higher than the healthcare sector average of 14. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 470.46% in the past year. It has overperformed other stocks in the healthcare sector by 566 percentage points.

Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 43, which is 29 points higher than the healthcare sector average of 14. It passed 3 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 6.06% in the past year. It has overperformed other stocks in the healthcare sector by 101 percentage points.

62.31% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 31.37% over the next year.

5.48% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.7% of healthcare stocks are rated B (Buy), 47.95% are rated C (Hold), 27.02% are rated D (Sell), and 6.85% are rated F (Strong Sell).